Compare · MO vs OBIO
MO vs OBIO
Side-by-side comparison of Altria Group Inc. (MO) and Orchestra BioMed Holdings Inc. (OBIO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MO and OBIO operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- MO is the larger of the two at $114.34B, about 377.5x OBIO ($302.9M).
- Over the past year, MO is up 4.3% and OBIO is up 83.8% - OBIO leads by 79.5 points.
- OBIO has been more active in the news (10 items in the past 4 weeks vs 5 for MO).
- MO has more recent analyst coverage (21 ratings vs 9 for OBIO).
- Company
- Altria Group Inc.
- Orchestra BioMed Holdings Inc.
- Price
- $69.99+2.21%
- $5.04-0.10%
- Market cap
- $114.34B
- $302.9M
- 1M return
- +2.53%
- +22.45%
- 1Y return
- +4.28%
- +83.79%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NYSE
- NASDAQ
- IPO
- 2020
- News (4w)
- 5
- 10
- Recent ratings
- 21
- 9
Altria Group Inc.
Altria Group, Inc., through its subsidiaries, manufactures and sells cigarettes, oral tobacco products, and wine in the United States. It offers cigarettes primarily under the Marlboro brand; cigars principally under the Black & Mild brand; and moist smokeless tobacco products under the Copenhagen, Skoal, Red Seal, and Husky brands, as well as provides on! oral nicotine pouches. The company also produces and sells varietal and blended table wines, and sparkling wines under the Chateau Ste. Michelle and 14 Hands names; and imports and markets Antinori, Torres, and Villa Maria Estate wines, as well as Champagne Nicolas Feuillatte in the United States. In addition, it provides finance leasing services primarily in transportation, power generation, real estate, and manufacturing equipment industries. The company sells its tobacco products primarily to wholesalers, including distributors; and large retail organizations, such as chain stores. Altria Group, Inc. was founded in 1822 and is headquartered in Richmond, Virginia.
Latest MO
- Altria Group Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Altria Announces Election of Steve Presley to Altria’s Board of Directors
- Altria Increases Quarterly Dividend to $1.11 Per Share
- Altria Announces Arrangement with Philip Morris International to Enhance Operational Efficiency
- Philip Morris International Announces Contract Manufacturing Collaboration with Altria
- SEC Form 10-Q filed by Altria Group Inc.
- Altria Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Altria Reports 2026 Second-Quarter and First-Half Results; Narrows 2026 Full-Year Earnings Guidance
- Cadiz Inc. Announces CFO Succession
- BTIG Research initiated coverage on Altria
Latest OBIO
- Chief Financial Officer Taylor Andrew Lawrence covered exercise/tax liability with 3,076 shares, decreasing direct ownership by 0.52% to 589,989 units (SEC Form 4) to cover taxes
- Principal Accounting Officer Aiello Joshua covered exercise/tax liability with 203 shares, decreasing direct ownership by 1% to 18,441 units (SEC Form 4) to satisfy withholding tax
- Officer Sherman Darren bought $10,660 worth of shares (2,000 units at $5.33) and covered exercise/tax liability with 4,925 shares, decreasing direct ownership by 0.43% to 1,149,402 units (SEC Form 4) to satisfy tax liability
- Orchestra BioMed to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
- Orchestra BioMed to Participate in the Wells Fargo 21st Annual Healthcare Conference
- Director Mack John Prosper covered exercise/tax liability with 4,885 shares, decreasing direct ownership by 7% to 66,544 units (SEC Form 4) (tax liability)
- Director Fain Eric S covered exercise/tax liability with 5,145 shares (SEC Form 4) (withholding obligation)
- Director Pacitti David covered exercise/tax liability with 3,761 shares, decreasing direct ownership by 6% to 54,750 units (SEC Form 4) to satisfy withholding tax
- Orchestra BioMed Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates
- SEC Form 10-Q filed by Orchestra BioMed Holdings Inc.